Press releases

New in vitro and clinical efficacy data have been published; Sphingomonas hydrophobicum extract, the active substance of Hebelys®,...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...

Major Steven Zumbrun (USAMRIID [1] , U.S. Department of Defense) presented data on the in vitro assessment of DNV3681 against pathogens...

The tests aimed at validating the dosage required have confirmed a very good efficacy of the ingredient The teams are working to develop a...

Dow has selected an extract belonging to the DEINOVE proprietary strains’ bank to launch a new cosmetic active ingredient for skin care...

Her proven experience in the beauty industry, particularly within the L'Oréal Group, will be a key asset in DEINOVE's innovation approach...

The USAMRIID (United States Army Medical Research Institute of Infectious Diseases) evaluated DNV3681 against Bacillus anthracis that...

Having reached a sufficient number of clinical centers, Phase II clinical trial testing the antibiotic candidate DNV3837 in Clostridioides[...

DEINOVE has developed a unique bioproduction process that leads to the first 100% pure Phytoene with an anti-aging action which mechanism...

Georges GAUDRIAULT, Scientific Director of DEINOVE, will give a talk at the ECCMID, at the ‘Therapeutics pipeline corner’, on this coming...